About this episode

Jonathan Sporn discusses the development of next-gen psychedelic medicines and a significant partnership with AbbVie.

Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in a partnership with AbbVie worth up to $1.2B. In this episode, we discuss: • Why Gilgamesh is building psychedelic medicines the way large pharma would • The thesis behind short-acting psychedelics and why long-duration trips are impractical...

Explore listener stats, chart rankings, contacts and more on the Business Trip podcast page.